4-hydroxyisoleucine and Obesity

4-hydroxyisoleucine has been researched along with Obesity* in 2 studies

Reviews

1 review(s) available for 4-hydroxyisoleucine and Obesity

Article	Year
4-Hydroxyisoleucine from Fenugreek (Trigonella foenum-graecum): Effects on Insulin Resistance Associated with Obesity. Molecules (Basel, Switzerland), 2016, Nov-22, Volume: 21, Issue:11 Topics: Animals; Glucose; Humans; In Vitro Techniques; Insulin Resistance; Isoleucine; Liver; Liver Function Tests; MAP Kinase Signaling System; Obesity; Plant Extracts; Trigonella	2016

Other Studies

1 other study(ies) available for 4-hydroxyisoleucine and Obesity

Article	Year
Insulinotropic agent ID-1101 (4-hydroxyisoleucine) activates insulin signaling in rat. American journal of physiology. Endocrinology and metabolism, 2004, Volume: 287, Issue:3 ID-1101 (4-hydroxyisoleucine), an amino acid extracted from fenugreek seeds, exhibits an interesting glucose-dependent insulin-stimulating activity. The present study was undertaken to investigate a possible extrapancreatic effect of ID-1101 on insulin signaling and action besides its previously described insulinotropic action. Insulin-sensitizing effects of ID-1101 were investigated in rat in vivo by three different approaches: 1) using euglycemic hyperinsulinemic clamps in two different rat models of insulin resistance, i.e., Zucker fa/fa rats and rats fed a sucrose-lipid diet; 2) measuring liver and muscle phosphatidylinositol (PI) 3-kinase activity after an acute injection of ID-1101 in normal and insulin-resistant diabetic rats; and 3) after chronic treatment in two rat models of insulin resistance. Euglycemic hyperinsulinemic clamp experiments revealed that ID-1101 can improve insulin resistance through an increase of peripheral glucose utilization rate in sucrose-lipid-fed rats and by decreasing hepatic glucose production in Zucker fa/fa rats. Moreover, we demonstrated that a single injection of ID-1101 activates the PI 3-kinase activity in liver and muscle from normal rats but also in muscle from diabetic rats. Finally, chronic ID-1101 treatment significantly reduced insulinemia in type 2 diabetic rats and reduced the progression of hyperinsulinemia in insulin-resistant obese Zucker fa/fa rats. These findings clearly demonstrate that ID-1101 can reduce insulin resistance through activation of the early steps of insulin signaling in peripheral tissues and in liver. In summary, ID-1101, besides its insulinotropic effect, directly improves insulin sensitivity, making it a potentially very valuable therapeutic agent for diabetes treatment. Topics: Animals; Diabetes Mellitus, Experimental; Diet; Enzyme Activation; Glucose; Glucose Clamp Technique; Hyperinsulinism; Insulin; Insulin Resistance; Isoleucine; Lipids; Liver; Male; Muscle, Skeletal; Niacinamide; Obesity; Phosphatidylinositol 3-Kinases; Rats; Rats, Sprague-Dawley; Rats, Zucker; Signal Transduction; Sucrose	2004

Article

Year

Insulinotropic agent ID-1101 (4-hydroxyisoleucine) activates insulin signaling in rat.

American journal of physiology. Endocrinology and metabolism, 2004, Volume: 287, Issue:3

ID-1101 (4-hydroxyisoleucine), an amino acid extracted from fenugreek seeds, exhibits an interesting glucose-dependent insulin-stimulating activity. The present study was undertaken to investigate a possible extrapancreatic effect of ID-1101 on insulin signaling and action besides its previously described insulinotropic action. Insulin-sensitizing effects of ID-1101 were investigated in rat in vivo by three different approaches: 1) using euglycemic hyperinsulinemic clamps in two different rat models of insulin resistance, i.e., Zucker fa/fa rats and rats fed a sucrose-lipid diet; 2) measuring liver and muscle phosphatidylinositol (PI) 3-kinase activity after an acute injection of ID-1101 in normal and insulin-resistant diabetic rats; and 3) after chronic treatment in two rat models of insulin resistance. Euglycemic hyperinsulinemic clamp experiments revealed that ID-1101 can improve insulin resistance through an increase of peripheral glucose utilization rate in sucrose-lipid-fed rats and by decreasing hepatic glucose production in Zucker fa/fa rats. Moreover, we demonstrated that a single injection of ID-1101 activates the PI 3-kinase activity in liver and muscle from normal rats but also in muscle from diabetic rats. Finally, chronic ID-1101 treatment significantly reduced insulinemia in type 2 diabetic rats and reduced the progression of hyperinsulinemia in insulin-resistant obese Zucker fa/fa rats. These findings clearly demonstrate that ID-1101 can reduce insulin resistance through activation of the early steps of insulin signaling in peripheral tissues and in liver. In summary, ID-1101, besides its insulinotropic effect, directly improves insulin sensitivity, making it a potentially very valuable therapeutic agent for diabetes treatment.

Topics: Animals; Diabetes Mellitus, Experimental; Diet; Enzyme Activation; Glucose; Glucose Clamp Technique; Hyperinsulinism; Insulin; Insulin Resistance; Isoleucine; Lipids; Liver; Male; Muscle, Skeletal; Niacinamide; Obesity; Phosphatidylinositol 3-Kinases; Rats; Rats, Sprague-Dawley; Rats, Zucker; Signal Transduction; Sucrose

2004